Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Multiple sclerosis Clinical criteria: Treatment Phase: Initial treatment The condition must be diagnosed as clinically definite relapsing-remitting multiple sclerosis by magnetic resonance imaging of the brain and/or spinal cord; OR The condition must be diagnosed as clinically definite relapsing-remitting multiple sclerosis, with written certification provided by a radiologist that a magnetic resonance imaging scan is contraindicated because of the risk of physical (not psychological) injury to the patient, AND Patient must have experienced at least 2 documented attacks of neurological dysfunction, believed to be due to multiple sclerosis, in the preceding 2 years of commencing a PBS-subsidised disease modifying therapy for this condition, AND Patient must be ambulatory (without assistance or support). Treatment criteria: Must be treated by a medical practitioner; OR Must be treated by a nurse practitioner in consultation with a specialist physician. Where applicable, the date of the magnetic resonance imaging scan must be recorded in the patient's medical records.
“The mechanisms by which interferon beta-1b exerts its actions in multiple sclerosis (MS) are not clearly understood. However, it is known that the biological response-modifying properties of interferon beta-1b are mediated through its interaction with specific cell receptors found on the surface of human cells.”
“Mean terminal elimination half-life and steady-state volume of distribution were estimated to be at most 4.3 hours and 2.88 L/kg.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Interferons have been reported to cause a down regulation of hepatic cytochrome P450- dependent enzymes in humans and animals. Caution should be exercised when BETAFERON is administered in combination with drugs that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance.”